Physician profile
David Cao
NPI 1366972143
$5,744.46
in general payments reported to CMS, 2019-2025
26 companies · $1,415 in 2025
The $1,415 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.07 · 2020: $26.81 · 2021: $231 · 2022: $1,631 · 2023: $2,070 · 2024: $349 · 2025: $1,415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,609 · Education: $1,500 · Consulting Fee: $375 · Honoraria: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,608.93 |
| Education | $1,500.00 |
| Consulting Fee | $375.00 |
| Honoraria | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,500.00 | 2022-2023 | Da Vinci Surgical System |
| Teleflex LLC | $668.26 | 2022-2025 | Barrigel, Urolift |
| Boston Scientific Corporation | $434.32 | 2020-2025 | Lithovue, Axonics, Ams 700 Cxr Rte Kit |
| Olympus America INC. | $416.40 | 2023-2025 | Itind System |
| Axonics, INC. | $384.68 | 2021-2024 | Axonics, Bulkamid |
| Verathon INC. | $375.00 | 2025 | Npd Clinical Study |
| Urovant Sciences INC | $127.57 | 2022 | |
| Coloplast Corp | $119.71 | 2022-2024 | Speedicath |
| Astrazeneca Pharmaceuticals Lp | $112.95 | 2023 | Lynparza |
| Merck Sharp & Dohme LLC | $91.76 | 2022-2025 | Keytruda, Lynparza |
| 180 Medical, INC. | $64.92 | 2023-2025 | Gentlecath Glide, Cure Catheter |
| Myriad Genetic Laboratories, INC. | $61.49 | 2023-2024 | Prolaris |
| Procept Biorobotics Corporation | $59.72 | 2024 | Aquabeam System |
| Astellas Pharma US INC | $58.95 | 2022-2023 | Xtandi |
| Endo USA, INC. | $44.87 | 2024-2025 | Edex, Xiaflex, Aveed |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $30.35 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $24.75 | 2025 | |
| Tolmar Pharmaceuticals, INC. | $23.04 | 2022 | |
| Abbvie INC. | $22.63 | 2022 | |
| Travere Therapeutics, INC. | $22.07 | 2019 | |
| Ferring Pharmaceuticals INC. | $20.11 | 2025 | Adstiladrin |
| Tolmar, INC. | $17.60 | 2025 | Eligard |
| Pacira Pharmaceuticals Incorporated | $16.61 | 2024 | Exparel, Zilretta, Iovera |
| Vertex Pharmaceuticals Incorporated | $16.28 | 2025 | |
| Karl Storz Endoscopy-America | $15.94 | 2025 | N.A. |
| Medtronic, INC. | $14.48 | 2023 | Interstim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.